

March 13, 2024

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

Presentation of the research results of Healios' eNK cells on mesothelioma at AACR Annual Meeting 2024

HEALIOS K.K. (“Healios”) announces that we will make poster presentations of our research results of joint research with Hyogo Medical University on the efficacy of eNK cells*, which we are researching and developing, in mesothelioma at [AACR \(American Association of Cancer Research\) Annual Meeting 2024](#) in San Diego, California from April 5 to 10, 2024.

We will present a poster for eNK cells. Please see below for details.

Date of presentation: Monday, April 8, 2024

Venue: Poster Section 2 at San Diego Convention Center, San Diego, CA

Session: CAR-NK, NK Engagers, and NK Modulators / Immunology

Published Abstract Number: 1336

Poster Board No.: 19

Title: Verification of the effect of human allogeneic iPSC cell-derived gene-engineered NK cells (eNK cells HLCN061) on mesothelioma

Presenter: Dr. Seiji Matsumoto, MD, Department of Thoracic Surgery, Hyogo Medical University

* eNK cells

(Development code: HLCN061)

Healios' eNK cells are an iPSC-derived NK cell therapy with several functional enhancements achieved through gene-editing including enhanced recognition of and cytotoxicity towards cancer, improved persistence, increased capability to migrate to and infiltrate solid tumors, and the ability to recruit host immune cells. Healios has succeeded in developing eNK cells through its own research and has confirmed the anti-tumor effect of eNK cells in mice engrafted with human lung cancer cells and human liver cancer cells. In joint research with [the National Cancer Center Japan](#) (“the NCCJ”) Healios is evaluating the antitumor effect of eNK cells in a PDX mouse disease model created using the NCCJ's JPDX samples. Healios is also conducting joint research using eNK cells for hepatocellular carcinoma with [Hiroshima University](#) and for mesothelioma with [Hyogo Medical University](#). Healios is continuing with in vitro and in vivo testing of its eNK cell therapy in preparation for its first clinical trials. In addition to advancing eNK cells as a monotherapy and in combination with existing drugs, Healios is developing a dual CAR-eNK cell product, in which chimeric antigen receptors (CARs) that specifically recognize cancer antigens are introduced into the eNK to facilitate enhanced targeting of certain solid cancers.

About Healios:

Healios is Japan's leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of

regenerative medicines in Japan, where it has established a proprietary, gene-edited “universal donor” induced pluripotent stem cell (iPSC) line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios’ lead iPSC-derived cell therapy candidate, HLCN061, is a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene editing. Its near-term pipeline includes the somatic stem cell product HLCM051, which has been evaluated in Japan in Phase 2/3 and Phase 2 trials in ischemic stroke and acute respiratory distress syndrome (ARDS), respectively. Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593).

<https://www.healios.co.jp/en>

Contact:

IR & Finance and Accounting Division

HEALIOS K.K.

E-mail: ir@healios.jp